Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 3
2004 3
2005 3
2006 3
2007 1
2008 4
2009 4
2010 5
2011 8
2012 7
2013 11
2014 6
2015 8
2016 6
2017 3
2018 12
2019 6
2020 12
2021 12
2022 7
2023 7
2024 10
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

128 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk NWCJ, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P; PERSEUS Trial Investigators. Sonneveld P, et al. N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12. N Engl J Med. 2024. PMID: 38084760 Clinical Trial.
Recommendations for Management of Secondary Antibody Deficiency in Multiple Myeloma.
Giralt S, Jolles S, Kerre T, Lazarus HM, Mustafa SS, Papanicolaou GA, Ria R, Vinh DC, Wingard JR. Giralt S, et al. Among authors: ria r. Clin Lymphoma Myeloma Leuk. 2023 Oct;23(10):719-732. doi: 10.1016/j.clml.2023.05.008. Epub 2023 May 23. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37353432 Free article. Review.
Angiogenesis in multiple myeloma.
Vacca A, Ria R, Reale A, Ribatti D. Vacca A, et al. Among authors: ria r. Chem Immunol Allergy. 2014;99:180-96. doi: 10.1159/000353312. Epub 2013 Oct 17. Chem Immunol Allergy. 2014. PMID: 24217610 Review.
Improvement of daratumumab- or elotuzumab-mediated NK cell activity by the bi-specific 4-1BB agonist, DARPin α-FAPx4-1BB: A preclinical study in multiple myeloma.
Saltarella I, Link A, Lamanuzzi A, Reichen C, Robinson J, Altamura C, Melaccio A, Solimando AG, Ria R, Mariggiò MA, Vacca A, Frassanito MA, Desaphy JF. Saltarella I, et al. Among authors: ria r. Biomed Pharmacother. 2024 Jul;176:116877. doi: 10.1016/j.biopha.2024.116877. Epub 2024 Jun 7. Biomed Pharmacother. 2024. PMID: 38850654 Free article.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.
Martino EA, Palmieri S, Galli M, Derudas D, Mina R, Della Pepa R, Zambello R, Vigna E, Bruzzese A, Mangiacavalli S, Zamagni E, Califano C, Musso M, Conticello C, Cerchione C, Mele G, Di Renzo N, Offidani M, Tarantini G, Casaluci GM, Rago A, Ria R, Uccello G, Barilà G, Palumbo G, Pettine L, Vincelli ID, Brunori M, Accardi F, Amico V, Amendola A, Fontana R, Bongarzoni V, Rossini B, Cotzia E, Gozzetti A, Rizzi R, Sgherza N, Reddiconto G, Maroccia A, Franceschini L, Bertuglia G, Nappi D, Barbieri E, Gamberi B, Petrucci MT, Di Raimondo F, Neri A, Morabito F, Musto P, Gentile M. Martino EA, et al. Among authors: ria r. Hematol Oncol. 2024 Jul;42(4):e3290. doi: 10.1002/hon.3290. Hematol Oncol. 2024. PMID: 38818978
Identify multiple myeloma stem cells: Utopia?
Saltarella I, Lamanuzzi A, Reale A, Vacca A, Ria R. Saltarella I, et al. Among authors: ria r. World J Stem Cells. 2015 Jan 26;7(1):84-95. doi: 10.4252/wjsc.v7.i1.84. World J Stem Cells. 2015. PMID: 25621108 Free PMC article. Review.
Measurable therapeutic antibody in serum as potential predictive factor of response to anti-CD38 therapy in non-IgG-k myeloma patients.
Gigliotta E, Plano F, Corsale G, Corsale AM, Aquilina C, Speciale M, Rizzuto A, Martino EA, Leotta D, Solimando AG, Ria R, Gentile M, Siragusa S, Botta C. Gigliotta E, et al. Among authors: ria r. Exp Hematol Oncol. 2024 Aug 6;13(1):82. doi: 10.1186/s40164-024-00547-x. Exp Hematol Oncol. 2024. PMID: 39107786 Free PMC article.
Comprehensive analysis of clinical outcomes, infectious complications and microbiological data in newly diagnosed multiple myeloma patients: a retrospective observational study of 92 subjects.
Desantis V, Borrelli P, Panebianco T, Fusillo A, Bochicchio D, Solito A, Pappagallo F, Mascolo A, Ancona A, Cicco S, Cerchione C, Romano A, Montagnani M, Ria R, Vacca A, Solimando AG. Desantis V, et al. Among authors: ria r. Clin Exp Med. 2024 Jun 27;24(1):137. doi: 10.1007/s10238-024-01411-2. Clin Exp Med. 2024. PMID: 38937383 Free PMC article.
128 results